

Tobias Klatte

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4498761/tobias-klatte-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175
papers

5,290
citations

39
h-index

65
g-index

200
ext. papers

6,550
ext. citations

4.6
avg, IF

5.52
L-index

#	Paper	IF	Citations
175	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.. <i>World Journal of Urology</i> , 2022 , 1	4	0
174	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium.. <i>Minerva Urology and Nephrology</i> , 2022 , 74, 186-193	2.3	1
173	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.. <i>European Urology</i> , 2022 ,	10.2	29
172	Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group.. <i>World Journal of Urology</i> , 2022 , 1	4	
171	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.. <i>European Urology</i> , 2021 ,	10.2	4
170	Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC. <i>World Journal of Urology</i> , 2021 , 40, 739	4	0
169	Risk models for recurrence and survival after kidney cancer: a systematic review.. <i>BJU International</i> , 2021 ,	5.6	3
168	Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic review. <i>Minerva Urology and Nephrology</i> , 2021 ,	2.3	5
167	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021 , 79, 339-342	10.2	42
166	Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. <i>World Journal of Urology</i> , 2021 , 39, 3823-3831	4	1
165	Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?. <i>BJU International</i> , 2021 , 128, 386-394	5.6	4
164	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e92-e99	3.3	5
163	Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). <i>European Urology Oncology</i> , 2021 , 4, 256-263	6.7	7
162	Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis. <i>BJU International</i> , 2021 , 128, 131-143	5.6	2
161	Reproducibility of CT-based radiomic features against image resampling and perturbations for tumour and healthy kidney in renal cancer patients. <i>Scientific Reports</i> , 2021 , 11, 11542	4.9	3
160	Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter Collaboration. <i>European Urology</i> , 2021 , 79, 133-140	10.2	15
159	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021 , 4, 473-482	6.7	7

158	A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound. <i>European Urology Focus</i> , 2021 , 7, 407-419	5.1	7
157	Standard Semen Parameters Sperm Kinematics to Predict Sperm DNA Damage. <i>World Journal of Men's Health</i> , 2021 , 39, 116-122	6.8	2
156	Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. <i>World Journal of Urology</i> , 2021 , 39, 3377-3383	4	1
155	Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium. <i>World Journal of Urology</i> , 2021 , 39, 2969-2975	4	5
154	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020 , 12, 23	14.4	37
153	Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <i>European Urology Oncology</i> , 2020 , 3, 168-173	6.7	9
152	Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort. <i>BJU International</i> , 2020 , 125, 561-567	5.6	5
151	Reply by Authors. <i>Journal of Urology</i> , 2020 , 203, 503-504	2.5	1
150	Chronic Kidney Disease After Partial Nephrectomy in Patients With Preoperative Inconspicuous Renal Function - Curiosity or Relevant Issue?. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e754-e761	3.3	6
149	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. <i>Journal of Urology</i> , 2020 , 203, 496-504	2.5	37
148	The 1999 and 2010 WHO reference values for human semen analysis to predict sperm DNA damage: A comparative study. <i>Reproductive Biology</i> , 2020 , 20, 379-383	2.3	1
147	Incidence and preoperative predictors for major complications following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020 , 9, 1786-1793	2.3	1
146	Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. <i>World Journal of Urology</i> , 2020 , 38, 1525-1533	4	1
145	External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 145-150	4.2	2
144	Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. <i>Oncology Letters</i> , 2019 , 18, 57-62	2.6	4
143	Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?. <i>Cancers</i> , 2019 , 11,	6.6	20
142	Systematic Review and Pooled Analysis of the Impact of Renorrhaphy Techniques on Renal Functional Outcome After Partial Nephrectomy. <i>European Urology Oncology</i> , 2019 , 2, 572-575	6.7	18
141	The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. <i>BMC Medicine</i> , 2019 , 17, 182	11.4	13

140	Therapeutic rationale of targeting BCG and immune checkpoints in non-muscle-invasive bladder cancer: Is this the Future?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 343-345	2.8	
139	Suture techniques during laparoscopic and robot-assisted partial nephrectomy: a systematic review and quantitative synthesis of peri-operative outcomes. <i>BJU International</i> , 2019 , 123, 923-946	5.6	36
138	Do We Truly Care About the Functional Outcomes for Renal Cancer Patients? Multidisciplinarity Is Still Far Away. <i>European Urology</i> , 2019 , 75, 349-350	10.2	9
137	Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU).	5.1	22
136	Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology. <i>European Urology Focus</i> , 2019 , 5, 1029-1057	5.1	17
135	Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice. <i>Urologia Internationalis</i> , 2018 , 101, 25-30	1.9	4
134	Epidemiology and screening for renal cancer. <i>World Journal of Urology</i> , 2018 , 36, 1341-1353	4	106
133	Magnetic resonance imaging as an adjunct diagnostic tool in computed tomography defined Bosniak IIF-III renal cysts: a multicenter study. <i>World Journal of Urology</i> , 2018 , 36, 905-911	4	11
132	Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. <i>World Journal of Urology</i> , 2018 , 36, 417-425	4	16
131	p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 94 e15-94 e21	2.8	5
130	Prognostic factors and prognostic models for renal cell carcinoma: a literature review. <i>World Journal of Urology</i> , 2018 , 36, 1943-1952	4	78
129	HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. <i>Pathology and Oncology Research</i> , 2018 , 24, 575-581	2.6	5
128	Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?. <i>European Urology Focus</i> , 2018 , 4, 972-977	5.1	7
127	Quality of life outcomes in patients with localised renal cancer: a literature review. <i>World Journal of Urology</i> , 2018 , 36, 1961-1972	4	11
126	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 1973-1980	4	5
125	Management of upper tract urothelial carcinoma 2018 , 373-382		
124	Genomics and clinical correlates of renal cell carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 1899-1911	4	24
123	Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. <i>Urologia Internationalis</i> , 2018 , 101, 197-200	1.9	7

122	Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 100-105	6.2	9
121	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. <i>BJU International</i> , 2018 , 121, 84-92	5.6	16
120	The Role of Ablation and Minimally Invasive Techniques in the Management of Small Renal Masses. <i>European Urology Oncology</i> , 2018 , 1, 395-402	6.7	8
119	A urinary microRNA (miR) signature for diagnosis of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 531.e1-531.e8	2.8	28
118	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. <i>BJU International</i> , 2017 , 119, 234-238	5.6	11
117	Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. <i>BJU International</i> , 2017 , 119, 268-275	5.6	16
116	Perioperative Allogenic Blood Transfusion in Renal Cell Carcinoma: Risk Factors and Effect on Long-term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e421-e427	3.3	11
115	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 335-341 ⁸	2.8	45
114	Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma after Nephrectomy. <i>European Urology</i> , 2017 , 71, 835-836	10.2	
113	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e681-e688	3.3	8
112	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project). <i>Scandinavian Journal of Urology</i> , 2017 , 51, 269-276	1.6	4
111	Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 460.e1-460.e8 ⁸	2.8	7
110	Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. <i>Urology</i> , 2017 , 106, 119-124	1.6	4
109	A practical guide and decision-making protocol for the management of complex renal cystic masses. <i>Arab Journal of Urology Arab Association of Urology</i> , 2017 , 15, 115-122	1.7	6
108	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 356-362 ^{2.8}	2.8	2
107	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 151.e17-151.e23	2.8	13
106	Organ Preservation Is Less Frequently Performed in Women Surgically Treated for Papillary Renal Cell Carcinoma-Results of a Comprehensive Multicenter Study. <i>Urology</i> , 2017 , 109, 107-114	1.6	2
105	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e223-e228	3.3	4

104	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e267-e273	3.3	25
103	Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. <i>PLoS ONE</i> , 2017 , 12, e0184173	3.7	19
102	Increase of papillary thyroid microcarcinoma and a plea for restrictive treatment: A retrospective study of 1,391 prospective documented patients. <i>Surgery</i> , 2016 , 159, 503-11	3.6	19
101	Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 483.e17-483.e24	2.8	40
100	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. <i>European Urology Focus</i> , 2016 , 2, 79-85	5.1	29
99	Surgical Management of Adrenocortical Carcinoma: Impact of Laparoscopic Approach, Lymphadenectomy, and Surgical Volume on Outcomes-A Systematic Review and Meta-analysis of the Current Literature. <i>European Urology Focus</i> , 2016 , 1, 241-250	5.1	13
98	Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. <i>Journal of Urology</i> , 2016 , 195, 1354-1361	2.5	20
97	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 233.e1-6	2.8	19
96	Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2016 , 196, 46-51	2.5	11
95	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2016 , 34, 1411-9	4	7
94	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. <i>World Journal of Urology</i> , 2016 , 34, 1155-61	4	4
93	Update on ablative therapies of renal tumors. <i>Current Opinion in Urology</i> , 2016 , 26, 410-6	2.8	11
92	Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. <i>Molecular Carcinogenesis</i> , 2016 , 55, 1458-66	5	25
91	Clinical Case Discussion: Kidney Cancer in Transplanted Kidney: The Interdisciplinary Nephrologic-Urologic View. <i>European Urology Focus</i> , 2016 , 2, 223-224	5.1	
90	Serum Adiponectin Predicts Cancer-specific Survival of Patients with Renal Cell Carcinoma. <i>European Urology Focus</i> , 2016 , 2, 197-203	5.1	9
89	Work-up of the Incidental Adrenal Mass. <i>European Urology Focus</i> , 2016 , 1, 217-222	5.1	3
88	Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy. <i>Urology</i> , 2016 , 95, 132-8	1.6	17
87	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 533.e1-533.e10	2.8	11

86	Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer. <i>European Urology</i> , 2015 , 68, 552-4	10.2	22
85	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. <i>European Urology</i> , 2015 , 68, 980-92	10.2	147
84	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 71.e21-6	2.8	26
83	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. <i>Nature</i> , 2015 , 521, 94-8	50.4	313
82	Intraoperative imprint cytology for real-time assessment of surgical margins during partial nephrectomy: A comparison with frozen section. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 67.e25-9	2.8	2
81	Novel biomarkers to predict response and prognosis in localized bladder cancer. <i>Urologic Clinics of North America</i> , 2015 , 42, 225-33, ix	2.9	8
80	Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. <i>World Journal of Urology</i> , 2015 , 33, 2087-93	4	6
79	Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2015 , 33, 2045-52	4	55
78	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 495.e15-22	2.8	10
77	Gender differences in incidence and outcomes of urothelial and kidney cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 585-92	5.5	49
76	The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 68.e1-7	2.8	49
75	Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. <i>World Journal of Urology</i> , 2015 , 33, 105-10	4	34
74	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015 , 116, 72-8	5.6	26
73	Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions. <i>World Journal of Urology</i> , 2015 , 33, 295-300	4	28
72	Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2015 , 33, 563-70	4	58
71	Re: cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2015 , 68, 737	10.2	
70	Partial nephrectomy driven by cavitron ultrasonic surgical aspirator under zero ischemia: a pilot study. <i>World Journal of Urology</i> , 2015 , 33, 2015-21	4	4
69	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. <i>Journal of Urology</i> , 2015 , 194, 1456-62	2.5	22

68	Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC). <i>BJU International</i> , 2015 , 115, 397-404	5.6	37
67	Non-Muscle-Invasive Bladder Cancer in the Elderly Patient. <i>Current Geriatrics Reports</i> , 2014 , 3, 42-47	1.3	3
66	A prospective study on surgical-site infections in thyroid operation. <i>Surgery</i> , 2014 , 155, 675-81	3.6	20
65	Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. <i>European Urology</i> , 2014 , 66, 379-85	10.2	21
64	Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). <i>BJU International</i> , 2014 , 113, E62-6	5.6	15
63	Words of wisdom. Re: radical prostatectomy or watchful waiting in early prostate cancer. <i>European Urology</i> , 2014 , 66, 386-7	10.2	2
62	The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation. <i>World Journal of Urology</i> , 2014 , 32, 597-605	4	33
61	Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2014 , 191, 1238-43	2.5	22
60	Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. <i>Journal of Urology</i> , 2014 , 191, 1209-17	2.5	74
59	Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. <i>European Urology</i> , 2014 , 66, 361-70	10.2	94
58	Prospective external validation of a bladder cancer detection model. <i>Journal of Urology</i> , 2014 , 192, 1343-8	3.8	30
57	The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 30.e9-13	2.8	31
56	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1239-47	4.6	24
55	Associations between presenting symptoms, clinicopathological parameters, and prognosis in a contemporary series of patients with renal cell carcinoma. <i>Korean Journal of Urology</i> , 2014 , 55, 505-10		12
54	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 625-30	2.8	20
53	Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). <i>BJU International</i> , 2013 , 111, E348-53	5.6	51
52	Intravesical bacillus Calmette-Guérin instillation therapy for non-muscle-invasive bladder cancer following solid organ transplantation. <i>Wiener Klinische Wochenschrift</i> , 2013 , 125, 189-95	2.3	6
51	Gender differences in benign renal masses. <i>World Journal of Urology</i> , 2013 , 31, 1051-7	4	9

50	Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. <i>Cancer</i> , 2013 , 119, 1547-54	6.4	44
49	Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies. <i>Wiener Klinische Wochenschrift</i> , 2013 , 125, 669-73	2.3	13
48	The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis. <i>Journal of Urology</i> , 2013 , 190, 717-22	2.5	17
47	The protease activated receptor 1 gene variation IVSn -14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma. <i>Journal of Urology</i> , 2013 , 190, 1392-7	2.5	14
46	Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. <i>Journal of Urology</i> , 2013 , 190, 1999-2004	2.5	83
45	Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. <i>European Urology</i> , 2012 , 61, 888-95	10.2	25
44	Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. <i>Cancer</i> , 2012 , 118, 82-90	6.4	69
43	Complex renal cystic masses: current standards and controversies. <i>International Urology and Nephrology</i> , 2012 , 44, 13-8	2.3	17
42	Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. <i>Cancer</i> , 2012 , 118, 5777-82	6.4	37
41	Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. <i>American Journal of Clinical Pathology</i> , 2012 , 137, 761-8	1.9	62
40	Age-specific PCA3 score reference values for diagnosis of prostate cancer. <i>World Journal of Urology</i> , 2012 , 30, 405-10	4	11
39	Renal cell carcinoma of native kidneys in renal transplant patients. <i>Current Opinion in Urology</i> , 2011 , 21, 376-9	2.8	24
38	Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies. <i>European Urology</i> , 2011 , 60, 435-43	10.2	85
37	Reply from Authors re: Giacomo Novara, Vincenzo Ficarra. Is Laparoscopic Cryoablation a Less Invasive and Effective Procedure to Treat Small Renal Masses? <i>Eur Urol</i> 2011;60:444B. <i>European Urology</i> , 2011 , 60, 446-447	10.2	
36	Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. <i>Journal of Urology</i> , 2011 , 185, 30-5	2.5	34
35	Perioperative, oncologic, and functional outcomes of laparoscopic renal cryoablation and open partial nephrectomy: a matched pair analysis. <i>Journal of Endourology</i> , 2011 , 25, 991-7	2.7	37
34	Interpersonal variability and present diagnostic dilemmas in Bosniak classification system. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011 , 45, 239-44		33
33	Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients. <i>BJU International</i> , 2010 , 105, 1260-5	5.6	45

32	Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. <i>Journal of Urology</i> , 2010 , 183, 2143-7	2.5	26
31	Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. <i>Journal of Urology</i> , 2010 , 184, 53-8	2.5	33
30	Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. <i>Journal of Urology</i> , 2010 , 183, 2403-8	2.5	26
29	Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. <i>Urology</i> , 2010 , 76, 541-6	1.6	11
28	Renal cell carcinoma Fuhrman grade and histological subtype correlate with complete polymorphic deletion of glutathione S-transferase M1 gene. <i>Journal of Urology</i> , 2010 , 183, 878-83	2.5	19
27	External validation of the preoperative anatomical classification for prediction of complications related to nephron-sparing surgery. <i>World Journal of Urology</i> , 2010 , 28, 531-5	4	52
26	Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. <i>European Urology</i> , 2010 , 57, 661-5	10.2	66
25	Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. <i>Cancer</i> , 2010 , 116, 4696-702	6.4	59
24	Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 746-53	2.2	164
23	Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. <i>Clinical Cancer Research</i> , 2009 , 15, 1162-9	12.9	139
22	Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 894-900	4	133
21	Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. <i>Cancer</i> , 2009 , 115, 1448-58	6.4	74
20	Editorial comment. <i>Journal of Urology</i> , 2009 , 182, 2606	2.5	0
19	Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. <i>Journal of Urology</i> , 2009 , 181, 1558-64; discussion 1563-4	2.5	58
18	High-intensity focused ultrasound for the treatment of renal masses: current status and future potential. <i>Current Opinion in Urology</i> , 2009 , 19, 188-91	2.8	26
17	The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. <i>BJU International</i> , 2008 , 101 Suppl 4, 45-8	5.6	13
16	Surveillance for renal cell carcinoma: why and how? When and how often?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 550-4	2.8	53
15	Pathobiology and prognosis of chromophobe renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 604-9	2.8	56

14	Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. <i>Journal of Urology</i> , 2008 , 179, 1719-26	2.5	125
13	Molecular biology of renal cortical tumors. <i>Urologic Clinics of North America</i> , 2008 , 35, 573-80; vi	2.9	27
12	The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. <i>Journal of Urology</i> , 2008 , 179, 61-6	2.5	98
11	Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2008 , 123, 395-400	7.5	134
10	Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. <i>Journal of Urology</i> , 2007 , 178, 35-40; discussion 40	2.5	47
9	Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. <i>Journal of Urology</i> , 2007 , 177, 2081-6; discussion 2086-7	2.5	42
8	Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. <i>Cancer</i> , 2007 , 109, 2257-67	6.4	298
7	Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. <i>BJU International</i> , 2007 , 99, 821-4	5.6	59
6	Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. <i>BJU International</i> , 2007 , 100, 21-5	5.6	54
5	Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 7388-93	7.0	152
4	Metastatic melanoma to the kidney presenting with renal vein tumor thrombus. <i>Urology</i> , 2007 , 69, 982.e7-9	1.6	11
3	Differential diagnosis of hypercalcemia in renal malignancy. <i>Urology</i> , 2007 , 70, 179.e7-8	1.6	5
2	Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. <i>Reviews in Urology</i> , 2007 , 9, 47-56	1	21
1	Risk stratification of high-grade Ta, CIS, and T1 urothelial carcinoma of the bladder	18-25	